+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, and Geographical Regions: Industry Trends and Global Forecasts, 2021-2030

  • ID: 5397828
  • Report
  • January 2021
  • Region: Global
  • 689 Pages
  • Roots Analysis
Given the Growing Demand for Interventions that Require Genetic Modification, the Market is Poised to Witness Substantial Growth in the Foreseen Future

FEATURED COMPANIES

  • 4D Molecular Therapeutics
  • BioCentriq
  • Eureka Biotechnology
  • InProTher
  • Norgen Biotek
  • Solid Biosciences

Over the past few years, a number of advanced therapy medicinal products, including cell and gene therapies, have been developed and approved for the treatment of a variety of disease indications. In fact, as of 2020, close to 15 such therapeutics have received marketing approval across different regions worldwide. Further, over 1,000 clinical trials focused on the evaluation of cell and gene therapies have been registered globally. It is worth noting that the clinical success of these therapies heavily relies on the design and type of gene delivery vector used (in therapy development and / or administration). At present, several innovator companies are actively engaged in developing / producing viral and / or non-viral vectors for gene therapies. In this context, it is worth mentioning that multiple viral and non-viral vector based vaccine candidates are being developed against the novel coronavirus (SARS-CoV-2). As of January 2021, the WHO revealed that more than 55 such vaccines are under evaluation, while two viral vector based vaccines (AZD1222 and Sputnik V), being developed by AstraZeneca / Oxford University and Gamaleya Research Institute / Acellena Contract Drug Research and Development, have been approved. This is indicative of the lucrative opportunities for companies that have the required capabilities to manufacture vectors and gene therapies.

Vaccine production is a challenging process and dealing with vectors (viral and non-viral) further adds to the complexity. Therefore, outsourcing is a common practice among biopharmaceutical companies when it comes to vector development and / or manufacturing. Several players have developed / are developing versatile technology platforms for designing and manufacturing different types of gene delivery vehicles. Innovation in this segment of the pharmaceutical industry is presently focused on the enhancement of transduction efficiency and improving gene delivery efficiencies. In fact, some vector-related technology providers claim that their proprietary solutions have the ability to enable further improvements in existing genetically modified therapeutic products, and / or optimize affiliated manufacturing processes. The viral / non-viral vectors and gene therapy manufacturing market has also witnessed significant partnership activity in the recent past, especially now that COVID-19 vaccine developers are actively approaching such companies for their services. Given the growing demand for interventions that require genetic modification, the vector and gene therapy manufacturing market is poised to witness substantial growth in the foreseen future.

Scope of the Report

The “Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4th Edition) by Scale of Operation (Preclinical, Clinical and Commercial), Type of Vector (AAV Vector, Adenoviral Vector, Lentiviral Vector, Retroviral Vector, Plasmid DNA and Others), Application Area (Gene Therapy, Cell Therapy and Vaccine), Therapeutic Area (Oncological Disorders, Inflammation & Immunological Diseases, Neurological Disorders, Ophthalmic Disorders, Muscle Disorders, Metabolic Disorders, Cardiovascular Disorders and Others), and Geographical Regions (North America, Europe, Asia Pacific, MENA, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the rapidly growing market of vector and gene therapy manufacturing, focusing on contract manufacturers, as well as companies having in-house manufacturing facilities. The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different regions of the globe. Amongst other elements, the report includes:

  • An overview of the current status of the market with respect to the players engaged (both industry and non-industry) in the manufacturing of viral, non-viral and other novel types of vectors, and gene therapies. It features information on the year of establishment, company size, location of headquarters, type of product manufactured (vector and gene therapy / cell therapy / vaccine), location of manufacturing facilities, purpose of production (in-house and contract services), scale of production (preclinical, clinical and commercial), type of vector manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others) and application area (gene therapy, cell therapy, vaccine and others).
  • An analysis of the technologies offered / developed by the companies engaged in this domain, based on the type of technology (viral vector and non-viral vector related platform), purpose of technology (vector manufacturing, gene delivery, product manufacturing, transduction / transfection, vector packaging and other), scale of production (preclinical, clinical and clinical), type of vector (AAV, adenoviral, lentiviral, retroviral, non-viral and other viral vectors), application area (gene therapy, cell therapy, vaccine and others). It also highlights the most prominent players within this domain, in terms of number of technologies.
  • A region-wise, company competitiveness analysis, highlighting key players engaged in the manufacturing of vectors and gene therapies, across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration supplier strength (based on experience in this field), manufacturing strength (type of product manufactured, number of manufacturing facilities and number of application areas), service strength (scale of operation, number of vectors manufactured and geographical reach) and company size (small-sized, mid-sized and large).
  • Elaborate profiles of key players based in North America, Europe and Asia-Pacific (shortlisted based on proprietary criterion). Each profile features an overview of the company / organization, its financial performance (if available), information related to its manufacturing facilities, vector manufacturing technology and an informed future outlook.
  • An analysis of recent collaborations and partnership agreements inked in this domain since 2015; it includes details of deals that were / are focused on the manufacturing of vectors, which were analyzed on the basis of year of partnership, type of partnership (manufacturing agreement, product / technology licensing, product development, merger / acquisition, research and development agreement, process development / optimization, service alliance, production asset / facility acquisition, supply agreement and others), scale of production (laboratory, clinical and commercial), type of vector (AAV, adenoviral, lentiviral, retroviral, plasmid and others), region and most active players (in terms of number of partnerships).
  • An analysis of the expansions related to viral vector and non-viral vector manufacturing, which have been undertaken since 2015, based on several parameters, such as year of expansion, type of expansion (new facility / plant establishment, facility expansion, technology installation / expansion, capacity expansion and others), type of vector (AAV, adenoviral, lentiviral, retroviral, plasmid and others), application area (gene therapy, cell therapy, vaccine and others) and geographical location of the expansion project.
  • An analysis evaluating the potential strategic partners (comparing vector based therapy developers and vector purification product developers) for vector and gene therapy product manufacturers, based on several parameters, such as developer strength, product strength, type of vector, therapeutic area, pipeline strength (clinical and preclinical).
  • An overview of other viral / non-viral gene delivery approaches that are currently being researched for the development of therapies involving genetic modification.
  • An in-depth analysis of viral vector and plasmid DNA manufacturers, featuring three schematic representations, namely [A] a three dimensional grid analysis, representing the distribution of vector manufacturers (on the basis of type of vector) across various scales of operation and purpose of production (in-house operations and contract manufacturing services), [B] a logo landscape of viral vector and plasmid DNA manufacturers based on the type of organization (industry and non-industry) and company size (small-sized, mid-sized and large), and [C] a schematic world map representation, highlighting the geographical location of key vector manufacturing hubs.
  • An analysis of the various factors that are likely to influence the pricing of vectors, featuring different models / approaches that may be adopted by product developers / manufacturers in order to decide the prices of proprietary vectors.
  • An estimate of the overall, installed vector manufacturing capacity of industry players based on the information available in the public domain, and insights generated via both secondary and primary research. The analysis also highlights the distribution of the global capacity by company size (small-sized, mid-sized and large), scale of operation (clinical and commercial), type of vector (viral vector and plasmid DNA) and region (North America, Europe, Asia Pacific and the rest of the world).
  • An informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength.
  • A discussion on the factors driving the market and various challenges associated with the vector production process.
  • An insightful discussion on the impact that the recent COVID-19 pandemic is likely to have on the vector and gene therapy manufacturing market. In addition, it features various strategies that different companies have adopted / may adopt in order to mitigate the challenges affiliated to the current global crisis.

One of the key objectives of this report was to evaluate the current market size and the future opportunity associated with the vector and gene therapy manufacturing market, over the coming decade. Based on various parameters, such as the likely increase in number of clinical studies, anticipated growth in target patient population, existing price variations across different types of vectors, and the anticipated success of gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] scale of operation (preclinical, clinical and commercial), [B] type of vector (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [C] application area (gene therapy, cell therapy and vaccine), [D] therapeutic area (oncological disorders, inflammation & immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and others) and [E] geographical region (North America, Europe, Asia Pacific, MENA, Latin America and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. For the purpose of the study, we invited over 180 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry and non-industry players:

  • Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences)
  • Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals)
  • Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences)
  • Cedric Szpirer (Founder, Executive & Scientific Director, Delphi Genetics)
  • Olivier Boisteau, (Co-Founder / President, Clean Cells), Laurent Ciavatti (Ex-Business Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells)
  • Alain Lamproye (Ex-President of Biopharma Business Unit, Novasep)
  • Joost van den Berg (Ex-Director, Amsterdam BioTherapeutics Unit)
  • Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital)
  • Eduard Ayuso, DVM, PhD (Scientific Director, Translational Vector Core, University of Nantes)
  • Colin Lee Novick (Managing Director, CJ Partners)
  • Semyon Rubinchik (Scientific Director, ACGT)
  • Astrid Brammer (Senior Manager Business Development, Richter-Helm)
  • Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Ex-Marketing Manager, Plasmid Factory)
  • Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing)
  • Beatrice Araud (ATMP Key Account Manager, EFS-West Biotherapy)
  • Nicolas Grandchamp (R&D Leader, GEG Tech)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players (contract service providers and in-house manufacturers) engaged in the development of vectors and gene therapies?
  • Which region are the current manufacturing hubs for vectors and gene therapies?
  • Which type of technologies are presently offered / being developed by the stakeholders engaged in this domain?
  • Which companies are likely to partner with viral and non-viral vector contract manufacturing service providers?
  • Which partnership models are commonly adopted by stakeholders engaged in this industry?
  • What type of expansion initiatives are being undertaken by players in this domain?
  • Which are the emerging viral and non-viral vectors used by players for the manufacturing of genetically modified therapies?
  • How is the recent COVID-19 pandemic likely to impact the viral and non-viral vector, and gene therapy manufacturing market?
  • What is the current, global demand for viral and non-viral vector, and gene therapies?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the vector and gene therapy manufacturing market in the short to mid-term, and long term.

Chapter 3 is a general introduction to the various types of viral and non-viral vectors. It includes a detailed discussion on the design, manufacturing requirements, advantages, limitations and applications of the currently available gene delivery vehicles. The chapter also features the clinical and approved pipeline of genetically modified therapies. Further, it includes a review of the latest trends and innovations in the contemporary vector manufacturing market.

Chapter 4 provides a detailed overview of more than 115 companies, featuring both contract service providers and in-house manufacturers that are actively involved in the production of viral vectors and / or gene therapies utilizing viral vectors. The chapter provides details on the year of establishment, company size, location of headquarters, type of product manufactured (vector and gene therapy / cell therapy / vaccine), location of manufacturing facilities, purpose of production (in-house and contract services), scale of production (preclinical, clinical and commercial), type of vector manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others) and application area (gene therapy, cell therapy, vaccine and others).

Chapter 5 provides an overview of around 65 industry players that are actively involved in the production of plasmid DNA and other non-viral vectors and / or gene therapies utilizing non-viral vectors. The chapter provides details on the the year of establishment, company size, location of headquarters, type of product manufactured (vector and gene therapy / cell therapy vaccine), location of plasmid DNA manufacturing facilities, purpose of production (in-house and contract services), scale of production (preclinical, clinical and commercial) and application area (gene therapy, cell therapy, vaccine and others).

Chapter 6 provides an overview of close to 90 non-industry players (academia and research institutes) that are actively involved in the production of vectors (both viral and non-viral) and / or gene therapies. The chapter provides details on the year of establishment, purpose of production (in-house and contract services), scale of production (preclinical, clinical and commercial), location of headquarters, type of vector manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others) and application area (gene therapy, cell therapy, vaccine and others).

Chapter 7 features an in-depth analysis of the technologies offered / developed by the companies engaged in this domain, based on the type of technology (viral vector and non-viral vector related platform), purpose of technology (vector manufacturing, gene delivery, product manufacturing, transduction / transfection, vector packaging and other), scale of production (preclinical, clinical and clinical), type of vector (AAV, adenoviral, lentiviral, retroviral, non-viral and other viral vectors), application area (gene therapy, cell therapy, vaccine and others) and leading technology providers.

Chapter 8 presents a detailed competitiveness analysis of vector manufacturers across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration supplier strength (based on its experience in this field), manufacturing strength (type of product manufactured, number of manufacturing facilities and number of application area), service strength (scale of production, number of vectors manufactured and geographical reach) and company size (small-sized, mid-sized and large).

Chapter 9 features detailed profiles of some of the key players that have the capability to manufacture viral vectors / plasmid DNA in North America. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.

Chapter 10 features detailed profiles of some of the key players that have the capability to manufacture viral vectors / plasmid DNA in Europe. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.

Chapter 11 features detailed profiles of some of the key players that have the capability to manufacture viral vectors / plasmid DNA in Asia-Pacific. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.

Chapter 12 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015-2020, covering analysis based on parameters such as year of partnership, type of partnership(manufacturing agreement, product / technology licensing, product development, merger / acquisition, research and development agreement, process development / optimization, service alliance, production asset / facility acquisition, supply agreement and others), scale of production (laboratory, clinical and commercial) and type of vector (AAV, adenoviral, lentiviral, retroviral, plasmid and others) most active players (in terms of number of partnerships).

Chapter 13 features an elaborate discussion and analysis of the various expansions that have been undertaken, since 2015. Further, the expansion activities in this domain have been analyzed on the basis of year of expansion, type of expansion (new facility / plant establishment, facility expansion, technology installation / expansion, capacity expansion and others), geographical location of the facility, type of vector (AAV, adenoviral, lentiviral, retroviral, plasmid and others) and application area (gene therapy, cell therapy, vaccine and others).

Chapter 14 highlights potential strategic partners (vector based therapy developers and vector purification product developers) for vector and gene therapy product manufacturers, based on several parameters, such as developer strength, product strength, type of vector, therapeutic area, pipeline strength (clinical and preclinical). The analysis aims to provide the necessary inputs to the product developers, enabling them to make the right decisions to collaborate with industry stakeholders with relatively more initiatives in the domain.

Chapter 15 provides detailed information on other viral / non-viral vectors (including alphavirus vectors, Bifidobacterium longum vectors, Listeria monocytogenes vectors, myxoma virus based vectors, Sendai virus based vectors, self-complementary vectors (improved versions of AAV), and minicircle DNA and Sleeping Beauty transposon vectors (non-viral gene delivery approach)) that are currently being utilized by pharmaceutical players to develop gene therapies, T-cell therapies and certain vaccines, as well. This chapter presents overview on all the aforementioned types of vectors, along with examples of companies that use them in their proprietary products. It also includes examples of companies that are utilizing specific technology platforms for the development / manufacturing of some of these novel vectors.

Chapter 16 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of viral vectors and plasmid DNA manufacturers on the basis of their scale of production and purpose of manufacturing (fulfilling in-house requirement / contract service provider). In addition, it consists of a logo landscape, representing the distribution of viral vector and plasmid DNA manufacturers based on the type of organization (industry / non-industry) and company size. The chapter also consists of six world map representations of manufacturers of viral / non-viral vectors (lentiviral, adenoviral, AAV and retroviral vectors, and plasmid DNA), depicting the most active geographies in terms of the presence of the organizations. Furthermore, we have provided a schematic world map representation to highlight the geographical locations of key vector manufacturing hubs across different continents.

Chapter 17 highlights our views on the various factors that may be taken into consideration while pricing viral vectors / plasmid DNA. It features discussions on different pricing models / approaches that manufacturers may choose to adopt to decide the prices of their proprietary products.

Chapter 18 features an informed analysis of the overall installed capacity of the vectors and gene therapy manufacturers. The analysis is based on meticulously collected data (via both secondary and primary research) on reported capacities of various small-sized, mid-sized and large companies, distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the vector production capabilities of the organizations by company size (small-sized, mid-sized and large), scale of operation (clinical and commercial), type of vector (viral vector and plasmid DNA) and region (North America, Europe, Asia Pacific and the rest of the world).

Chapter 19 features an informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies. This section offers an opinion on the required scale of supply (in terms of vector manufacturing services) in this market. For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vector-based therapies that have been registered till date. The data was analyzed on the basis of various parameters, such as number of annual clinical doses, trial location, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the marketed vector-based therapies, based on various parameters, such as target patient population, dosing frequency and dose strength.

Chapter 20 presents a comprehensive market forecast analysis, highlighting the likely growth of vector and gene therapy manufacturing market till the year 2030. We have segmented the financial opportunity on the basis of [A] type of vectors (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [B] applications (gene therapy, cell therapy and vaccine), [C] therapeutic area (oncological disorders, inflammation & immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and others), [D] scale of operation (preclinical, clinical and commercial) and [E] geography (North America, Europe, Asia Pacific, MENA, Latin America and rest of the world). Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.

Chapter 21 highlights the effect of recent coronavirus outbreak on the vector and gene therapy manufacturing market. It includes a brief discussion on the short-term and long-term impact of COVID-19 on the supply chain and market opportunity for vector and gene therapy manufacturers. In addition, it includes a brief section on strategies and action plans that pharmaceutical and biopharmaceutical companies are likely to adopt in order to prepare for supply chain disruptions in future.

Chapter 22 provides details on the various factors associated with popular viral vectors and plasmid DNA that act as market drivers and the various challenges associated with the production process. This information has been validated by soliciting the opinions of several industry stakeholders active in this domain.

Chapter 23 presents insights from the survey conducted on over 180 stakeholders involved in the development of different types of gene therapy vectors. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 24 summarizes the overall report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 25 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in the vector and gene therapy manufacturing domain. In this study, we spoke to Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences), Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences), Cedric Szpirer (Founder, Executive & Scientific Director, Delphi Genetics), Olivier Boisteau, (Co-Founder / President, Clean Cells), Laurent Ciavatti (Ex-Business Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells), Alain Lamproye (Ex-President of Biopharma Business Unit, Novasep), Joost van den Berg (Ex-Director, Amsterdam BioTherapeutics Unit), Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital), Eduard Ayuso, DVM, PhD (Scientific Director, Translational Vector Core, University of Nantes), Colin Lee Novick (Managing Director, CJ Partners), Semyon Rubinchik (Scientific Director, ACGT), Astrid Brammer (Senior Manager Business Development, Richter-Helm), Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Ex-Marketing Manager, Plasmid Factory), Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing), Beatrice Araud (ATMP Key Account Manager, EFS-West Biotherapy) and Nicolas Grandchamp (R&D Leader, GEG Tech).

Chapter 26 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 4D Molecular Therapeutics
  • BioCentriq
  • Eureka Biotechnology
  • InProTher
  • Norgen Biotek
  • Solid Biosciences

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Viral and Non-Viral Gene Transfer Techniques
3.3. Viral Vectors Used in Genetically Modified Therapies
3.4. Types of Viral Vectors
3.4.1. Adeno-associated Viral Vectors
3.4.2. Adenoviral Vectors
3.4.3. Lentiviral Vectors
3.4.4. Retroviral Vectors
3.4.5. Other Viral Vectors
3.4.5.1. Alphavirus
3.4.5.2. Foamy Virus
3.4.5.3. Herpes Simplex Virus
3.4.5.4. Sendai Virus
3.4.5.5. Simian Virus
3.4.5.6. Vaccinia Virus
3.5. Types of Non-Viral Vectors
3.5.1. Plasmid DNA
3.5.2. Liposomes, Lipoplexes and Polyplexes
3.5.3. Oligonucleotides
3.5.4. Other Non-Viral Vectors
3.6. Gene Delivery using Non-Viral Vectors
3.6.1. Biolistic Methods
3.6.2. Electroporation
3.6.3. Receptor Mediated Gene Delivery
3.6.4. Gene Activated Matrix (GAM)
3.7. Applications of Viral and Non-Viral Vectors
3.7.1. Type of Therapy
3.7.1.1. Cell and Gene Therapy
3.7.1.2. Vaccinology
3.8. Current / Ongoing Trends in Vector Development / Manufacturing
3.8.1. Vector Engineering
3.8.2. Cargo Engineering
3.9. Vector Manufacturing
3.9.1. Types of Vector Manufacturers
3.9.2. Viral Vector Manufacturing Processes
3.9.2.1 Vector Production
3.9.2.2. Adherent and Suspension Cultures
3.9.2.3. Unit Process Versus Multiple Parallel Processes
3.9.2.4. Cell Culture Systems for Production of Viral Vectors
3.9.2.5. Serum-Containing versus Serum-Free Media
3.9.3. Bioprocessing of Viral Vectors
3.9.3.1. AAV Vector Production
3.9.3.2. Adenoviral Vector Production
3.9.3.3. Lentiviral Vector Production
3.9.3.4. γ -Retroviral Vector Production
3.9.4. Key Challenges Associated with Vector Manufacturing
3.10. Future Perspectives

4. VIRAL VECTOR AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Viral Vector and Gene Therapy Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Product Manufactured
4.2.5. Analysis by Location of Vector Manufacturing Facilities
4.2.6. Analysis by Purpose of Production
4.2.7. Analysis by Scale of Production
4.2.8. Analysis by Location of Headquarters and Scale of Production
4.2.9. Analysis by Type of Vector Manufactured
4.2.10. Analysis by Scale of Production and Type of Vector Manufactured
4.2.11. Analysis by Application Area
4.2.12. Information on Production Capacity

5. PLASMID DNA AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Plasmid DNA and Gene Therapy Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Heat Map: Analysis by Company Size and Location of Headquarters
5.2.5. Analysis by Type of Product Manufactured
5.2.6. Analysis by Location of Plasmid DNA Manufacturing Facilities
5.2.7. Analysis by Purpose of Production
5.2.8. Analysis by Scale of Production
5.2.9. Analysis by Application Area
5.2.10. Information on Production Capacity

6. VECTOR AND GENE THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Vector and Gene Therapy Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Location of Vector Manufacturing Facilities
6.2.3. Analysis by Purpose of Production
6.2.4. Analysis by Scale of Production
6.2.5. Analysis by Type of Vector Manufactured
6.2.6. Analysis by Scale of Production and Type of Vector Manufactured
6.2.7. Analysis by Application Area

7. VECTOR AND GENE THERAPY MANUFACTURING TECHNOLOGIES: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Vector and Gene Therapy Manufacturing Technologies
7.2.1. Analysis by Type of Technology
7.2.2. Analysis by Purpose of Technology
7.2.3. Analysis by Scale of Production
7.2.4. Analysis by Type of Vector
7.2.5. Analysis by Application Area
7.2.6. Most Active Players: Analysis by Type of Technology
7.3. Concluding Remarks

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Vector and Gene Therapy: In-House Manufacturers
8.3.1. Players based in North America
8.3.2. Players based in Europe
8.3.3. Players based in Asia-Pacific and Rest of the World
8.4. Vector and Gene Therapy: Contract Manufacturing Organizations
8.4.1. Players based in North America
8.4.2. Players based in Europe
8.4.3. Players based in Asia-Pacific and Rest of the World
8.5.. Vector and Gene Therapy: Players Engaged in In-house and Contract Manufacturing
8.5.1. Players based in North America
8.5.2. Players based in Europe
8.5.3. Players based in Asia-Pacific and Rest of the World

9. VECTOR AND GENE THERAPY MANUFACTURERS IN NORTH AMERICA
9.1. Chapter Overview
9.2. Advanced BioScience Laboratories
9.2.1. Company Overview
9.2.2. Manufacturing Facilities
9.2.3. Recent Developments and Future Outlook
9.3. Aldevron
9.3.1. Company Overview
9.3.2. Manufacturing Facilities
9.3.3. Manufacturing Experience
9.3.4. Recent Developments and Future Outlook
9.4. Audentes Therapeutics
9.4.1. Company Overview
9.4.2. Manufacturing Facilities
9.4.3. Recent Developments and Future Outlook
9.5. BioReliance / SAFC Commercial (Merck KGaA)
9.5.1. Company Overview
9.5.2. Financial Information
9.5.3. Vector Manufacturing Technology Portfolio
9.5.4. Manufacturing Facilities
9.5.5. Recent Developments and Future Outlook
9.6. bluebird bio
9.6.1. Company Overview
9.6.2. Financial Information
9.6.3. Manufacturing Facilities
9.6.4. Manufacturing Experience
9.6.5. Recent Development and Future Outlook
9.7. Brammer Bio
9.7.1. Company Overview
9.7.2. Manufacturing Facilities
9.7.3. Manufacturing Experience
9.7.4. Recent Developments and Future Outlook
9.8. Emergent BioSolutions
9.8.1. Company Overview
9.8.2. Financial Information
9.8.3. Manufacturing Facilities
9.8.4. Recent Developments and Future Outlook
9.9. FUJIFILM Diosynth Biotechnologies
9.9.1. Company Overview
9.9.2. Financial Information
9.9.3. Manufacturing Facilities
9.9.4. Manufacturing Experience
9.9.5. Recent Developments and Future Outlook
9.1 MeiraGTx
9.10.1. Company Overview
9.10.2. Manufacturing Facilities
9.10.3. Recent Developments and Future Outlook
9.11. Other Companies
9.11.1. MassBiologics
9.11.1.1. Company Overview
9.11.1.2. Manufacturing Facilities
9.11.1.3. Recent Developments and Future Outlook
9.11.2. Spark Therapeutics
9.11.2.1. Company Overview
9.11.2.2. Financial Information
9.11.2.3. Manufacturing Facilities
9.11.2.4. Vector Manufacturing Technology Portfolio
9.11.2.5. Manufacturing Experience
9.11.2.6. Recent Developments and Future Outlook
9.11.3. Vigene Biosciences
9.11.3.1. Company Overview
9.11.3.2. Manufacturing Facilities
9.11.3.3. Vector Manufacturing Technology Portfolio
9.11.3.4. Manufacturing Experience
9.11.3.5. Recent Developments and Future Outlook

10. VECTOR AND GENE THERAPY MANUFACTURERS IN EUROPE
10.1. Chapter Overview
10.2. Biovian
10.2.1. Company Overview
10.2.2. Manufacturing Facilities
10.2.3. Recent Developments and Future Outlook
10.3. Centre for Process Innovation
10.3.1. Company Overview
10.3.2. Manufacturing Facilities
10.3.3. Recent Developments and Future Outlook
10.4. Cobra Biologics
10.4.1. Company Overview
10.4.2. Manufacturing Facilities
10.4.3. Vector Manufacturing Technology Portfolio
10.4.4. Manufacturing Experience
10.4.5. Recent Developments and Future Outlook
10.5. FinVector
10.5.1. Company Overview
10.5.2. Manufacturing Facilities
10.5.3. Vector Manufacturing Technology Portfolio
10.5.4. Manufacturing Experience
10.5.5. Recent Developments and Future Outlook
10.6. Kaneka Eurogentec
10.6.1. Company Overview
10.6.2. Manufacturing Facilities
10.6.3. Manufacturing Experience
10.6.4. Recent Developments and Future Outlook
10.7. Lonza
10.7.1. Company Overview
10.7.2. Financial Information
10.7.3. Vector Manufacturing Technology Portfolio
10.7.4. Manufacturing Facilities
10.7.5. Recent Developments and Future Outlook
10.8. MolMed
10.8.1. Company Overview
10.8.2. Financial Information
10.8.3. Manufacturing Facilities
10.8.4. Recent Developments and Future Outlook
10.9. Novasep
10.9.1. Company Overview
10.9.2. Financial Information
10.9.3. Manufacturing Facilities
10.9.4. Manufacturing Experience
10.9.5. Recent Developments and Future Outlook
10.10. Orchard Therapeutics
10.10.1. Company Overview
10.10.2. Manufacturing Facilities
10.10.3 Recent Developments and Future Outlook
10.11. Oxford BioMedica
10.11.1. Company Overview
10.11.2. Financial Information
10.11.3. Manufacturing Facilities
10.11.4. Vector Manufacturing Technology Portfolio
10.11.5. Manufacturing Experience
10.11.6. Recent Developments and Future Outlook
10.12. Richter-Helm
10.12.1. Company Overview
10.12.2. Manufacturing Facilities
10.12.3. Recent Developments and Future Outlook
10.13. Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
10.13.1. Company Overview
10.13.2. Financial Information
10.13.3. Manufacturing Facilities
10.13.4. Recent Developments and Future Outlook
10.14. uniQure
10.14.1. Company Overview
10.14.2. Financial Information
10.14.3. Manufacturing Facilities
10.14.4. Vector Manufacturing Technology Portfolio
10.14.5. Recent Developments and Future Outlook
10.15. Vibalogics
10.15.1. Company Overview
10.15.2. Manufacturing Facilities
10.15.3. Recent Developments and Future Outlook
10.16. VIVEbiotech
10.16.1. Company Overview
10.16.2. Vector Manufacturing Technology Portfolio
10.16.3. Manufacturing Facilities
10.16.4. Recent Developments and Future Outlook
10.17. Other Companies
10.17.1. Cell and Gene Therapy Catapult
10.17.1.1. Company Overview
10.17.1.2. Manufacturing Facilities
10.17.1.3. Recent Developments and Future Outlook

11. VECTOR AND GENE THERAPY MANUFACTURERS IN ASIA-PACIFIC
11.1. Chapter Overview
11.2. Wuxi AppTec
11.2.1. Company Overview
11.2.2. Financial Information
11.2.3. Manufacturing Facilities
11.2.4. Manufacturing Experience
11.2.5. Recent Developments and Future Outlook
11.3. Other Key Players

12. RECENT PARTNERSHIPS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Vector and Gene Therapy Manufacturing: Recent Partnerships
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Scale of Production
12.3.4. Analysis by Type of Vector
12.3.5. Analysis by Therapeutic Area
12.3.6. Most Active Players: Analysis by Number of Partnerships
12.3.7. Geographical Analysis
12.3.7.1. Intercontinental and Intracontinental Agreements
12.4. Other Collaborations

13. RECENT EXPANSIONS
13.1. Chapter Overview
13.2. Expansions Models
13.3. Vector and Gene Therapy Manufacturing: Recent Expansions
13.3.1. Analysis by Year of Expansion
13.3.2. Analysis by Type of Expansion
13.3.3. Analysis by Amount Invested by Key Players
13.3.4. Analysis by Scale of Production
13.3.5. Analysis by Type of Vector
13.3.6. Analysis by Application Area
13.3.7. Most Active Players: Analysis by Number of Expansions
13.3.8. Geographical Analysis
13.3.8.1. Analysis by Location of Expansion Project

14. STRATEGIC PARTNER ANALYSIS
14.1. Chapter Overview
14.2. Strategic Partner Analysis: Viral Vector based Therapy Developers
14.3. Methodology and Key Parameters
14.3.1. Opportunities for AAV Vector- based Therapy Developers
14.3.1.1. Most Likely Partners
14.3.1.2. Likely Partners
14.3.1.3. Less Likely Partners
14.3.1.4. Least Likely Partners
14.3.2. Opportunities for Adenoviral Vector based Therapy Developers
14.3.2.1. Most Likely Partners
14.3.2.2. Likely Partners
14.3.2.3. Less Likely Partners
14.3.2.4. Least Likely Partners
14.3.3. Opportunities for Lentiviral Vector based Therapy Developers
14.3.3.1. Most Likely Partners
14.3.3.2. Likely Partners
14.3.3.3. Less Likely Partners
14.3.3.4. Least Likely Partners
14.3.4. Opportunities for Retroviral Vector based Therapy Developers
14.3.4.1. Most Likely Partners
14.3.4.2. Likely Partners
14.3.4.3. Less Likely Partners
14.3.4.4. Least Likely Partners
14.3.5. Opportunities for Other Viral Vector based Therapy Developers
14.3.5.1. Most Likely Partners
14.3.5.2. Likely Partners
14.3.5.3. Less Likely Partners
14.3.5.4. Least Likely Partners
14.4. Strategic Partner Analysis: Viral Vector based Purification Product Developers
14.5. Methodology and Key Parameters
14.5.1. Opportunities for AAV based Purification Product Developers
14.5.1.1. Most Likely Partners
14.5.1.2. Likely Partners
14.5.2. Opportunities for Adenoviral Vector based Purification Product Developers
14.5.2.1. Most Likely Partners
14.5.2.2. Likely Partners
14.5.3. Opportunities for Lentiviral Vector based Purification Product Developers
14.5.3.1. Most Likely Partners
14.5.3.2. Likely Partners
14.5.4. Opportunities for Retroviral Vector based Purification Product Developers
14.5.4.1. Most Likely Partners
14.5.4.2. Likely Partners
14.5.5. Opportunities for Other Viral Vector based Purification Product Developers
14.5.5.1. Most Likely Partners
14.5.5.2. Likely Partners

15. EMERGING VECTORS
15.1. Chapter Overview
15.1.1. Alphavirus based Vectors
15.1.2. Anc80 based Vectors
15.1.3. Bifidobacterium longum based Vectors
15.1.4. Cytomegalovirus based Vectors
15.1.5. Listeria monocytogenes based Vectors
15.1.6. Minicircle DNA based Vectors
15.1.7. Myxoma Virus based Vectors
15.1.8. Self-Complementary Vectors
15.1.9. Sendai Virus based Vectors
15.1.10. Sleeping Beauty Transposons
15.1.11. Vaccinia Virus and Modified Vaccinia Ankara based Vectors

16. KEY INSIGHTS
16.1. Chapter Overview
16.2. Vector and Gene Therapy Manufacturers: Analysis by Purpose of Manufacturing, Type of Vector Manufactured and Scale of Operation
16.3. Vector and Gene Therapy Manufacturers: Analysis by Company Size and Type of Vector Manufactured
16.4. Vector and Gene Therapy Manufacturers: Prominent Geographical Hubs by Type of Organization
16.4.1. Contract Manufacturing Organizations
16.4.2. In-House Manufacturers
16.5. Vector and Gene Therapy Manufacturers: Analysis by Location of Manufacturing Facilities and Type of Vector Manufactured
16.5.1. AAV Vector Manufacturers
16.5.2. Adenoviral Vector Manufacturers
16.5.3. Lentiviral Vector Manufacturers
16.5.4. Retroviral Vector Manufacturers
16.5.5. Plasmid DNA Manufacturers

17. COST PRICE ANALYSIS
17.1. Chapter Overview
17.2. Factors Contributing to High Price of Viral Vector and Plasmid DNA based Therapies
17.3. Viral Vector and Plasmid DNA based Therapies: Pricing Models
17.3.1. On the Basis of Expert Opinions
17.3.2. On the Basis of Manufacturing Cost
17.3.2.1. On the Basis of Technology Used
17.3.2.2. On the Basis of Scale of Manufacturing
17.3.2.3. On the Basis of Type of Client
17.3.3. Prices of Different Types of Vectors
17.4. Concluding Remarks

18. CAPACITY ANALYSIS
18.1. Chapter Overview
18.2. Methodology and Key Assumptions
18.2. Global Installed Viral Vector and Gene Therapy Manufacturing Capacity
18.3. Global Installed Viral Vector Manufacturing Capacity
18.3.1. Analysis by Company Size
18.3.2. Analysis by Scale of Production
18.3.3. Analysis by Location of Manufacturing Facilities
18.4. Global Installed Plasmid DNA Manufacturing Capacity
18.4.1. Analysis by Company Size
18.4.2. Analysis by Scale of Production
18.4.3. Analysis by Location of Manufacturing Facilities
18.4. Concluding Remarks

19. DEMAND ANALYSIS
19.1. Chapter Overview
19.2. Assumptions and Methodology
19.3. Global Clinical Demand for Viral Vectors and Plasmid DNA, 2021-2030
19.3.1. Analysis by Type of Vector
19.3.2. Analysis by Type of Therapy
19.3.3. Analysis by Therapeutic Area
19.3.4. Analysis by Geographical Location
19.4. Global Commercial Demand for Viral Vectors and Plasmid DNA, 2021-2030
19.4.1. Analysis by Type of Vector
19.4.2. Analysis by Type of Therapy
19.4.3. Analysis by Therapeutic Area
19.4.4. Analysis by Geographical Location
19.5. Demand and Supply Analysis
19.5.1. Scenario 1
19.5.2. Scenario 2
19.5.3. Scenario 3

20. MARKET SIZING AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Scope of the Forecast
20.3. Forecast Methodology
20.4. Input Tables and Key Assumptions
20.5. Global Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030
20.5.1. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Distribution by Type of Vector Manufactured
20.5.1.1. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Market Attractiveness by Purpose of Manufacturing
20.5.2. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Distribution by Scale of Operation
20.5.3. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Distribution by Type of Vector Manufactured
20.5.4. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Distribution by Therapeutic Area
20.5.5. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Distribution by Application Area
20.5.6. Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030: Distribution by Key Geographical Regions
20.6. Current and Future Market Opportunity from Commercial Products
20.6.1. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2021-2030: Distribution by Type of Vector Manufactured
20.6.2. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2021-2030: Distribution by Therapeutic Area
20.6.3. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2021-2030: Distribution by Application Area
20.6.4. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions
20.6.4.1. AAV Vectors
20.6.4.1.1. AAV Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Therapeutic Area
20.6.4.1.2. AAV Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Application Area
20.6.4.1.3. AAV Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions
20.6.4.2. Adenoviral Vectors
20.6.4.2.1. Adenoviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Therapeutic Area
20.6.4.2.2. Adenoviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Application Area
20.6.4.2.3. Adenoviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions
20.6.4.3. Lentiviral Vectors
20.6.4.3.1. Lentiviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Therapeutic Area
20.6.4.3.2. Lentiviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Application Area
20.6.4.3.3. Lentiviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions
20.6.4.4. Retroviral Vectors
20.6.4.4.1. Retroviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Therapeutic Area
20.6.4.4.2. Retroviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Application Area
20.6.4.4.3. Retroviral Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions
20.6.4.5. Plasmid DNA
20.6.4.5.1. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Therapeutic Area
20.6.4.5.2. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Application Area
20.6.4.5.3. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions
20.7. Current and Future Market Opportunity for Clinical Candidates
20.7.1. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development
20.7.2. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Type of Vector Manufactured
20.7.3. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area
20.7.4. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions
20.7.4.1. AAV Vectors
20.7.4.1.1. AAV Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development
20.7.4.1.2. AAV Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area
20.7.4.1.3. AAV Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions
20.7.4.2. Adenoviral Vectors
20.7.4.2.1. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development
20.7.4.2.2. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area
20.7.4.2.3. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions
20.7.4.3. Lentiviral Vectors
20.7.4.3.1. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development
20.7.4.3.2. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area
20.7.4.3.3. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions
20.7.4.4. Retroviral Vectors
20.7.4.4.1. Retroviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development
20.7.4.4.2. Retroviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area
20.7.4.4.3. Retroviral Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions
20.7.4.5. Plasmid DNA
20.7.4.5.1. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development
20.7.4.5.2. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area
20.7.4.5.3. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions
20.8. Current and Future Market Opportunity from Preclinical Candidates
20.8.1. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Vector Manufactured
20.8.2. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Animal Model Used
20.8.3. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Therapeutic Area
20.8.4. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area
20.8.5. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Key Geographical Regions
20.8.5.1. AAV Vectors
20.8.5.1.1. AAV Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Animal Model Used
20.8.5.1.2. AAV Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area
20.8.5.1.3. AAV Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Key Geographical Regions
20.8.5.2. Adenoviral Vectors
20.8.5.2.1. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Animal Model Used
20.8.5.2.2. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area
20.8.5.2.3. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Key Geographical Regions
20.8.5.3. Lentiviral Vectors
16.8.5.3.1. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Animal Model Used
20.8.5.3.2. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area
20.8.5.3.3. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Key Geographical Regions
20.8.5.4. Retroviral Vectors
20.8.5.4.1. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Animal Model Used
20.8.5.4.2. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area
20.8.5.4.3. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Key Geographical Regions
20.8.5.5. Plasmid DNA
20.8.5.5.1. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Type of Animal Model Used
20.8.5.5.2. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area
20.8.5.5.3. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Key Geographical Regions
20.9 Current and Future Market opportunity from Vector-Based Vaccines
20.9.1. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2021-2030: Distribution by Scale of Operation
20.9.2. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2021-2030: Distribution by Type of Vector Manufactured
20.9.3. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2021-2030: Distribution by Therapeutic Area
20.9.4. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2021-2030: Distribution by Key Geographical Regions

21. IMPACT OF COVID-19 PANDEMIC ON THE VECTOR AND GENE THERAPY MANUFACTURING MARKET
21.1 Chapter Overview
21.2. Current Opinions and Recuperative Initiatives of Key Players
21.2.1. GE Healthcare (Cytiva)
21.2.2. Lonza
21.2.3. Pfizer
21.2.4. WuXi AppTec
21.3. Impact on Vector and Gene Therapy Manufacturing Market
21.4. Recuperative Strategies for Contract Service Providers
21.4.1. Strategies for Implementation in the Short / Mid Term
21.4.2. Strategies for Implementation in the Long Term

22. KEY DRIVERS AND CHALLENGES
22.1. Chapter Overview
22.2. Viral Vector and Plasmid DNA Manufacturing Market: Key Drivers and Challenges
22.2.1. AAV Vectors
22.2.2. Adenoviral Vectors
22.2.3. Lentiviral Vectors
22.2.4. Retroviral Vectors
22.2.5. Plasmid DNA
22.3. Concluding Remarks

23. SURVEY ANALYSIS
23.1. Chapter Overview
23.2. Analysis by Seniority Level of Respondents
23.3. Analysis by Purpose of Production
23.4. Analysis by Scale of Production
23.5. Analysis by Type of Vector Manufactured

24. CONCLUDING REMARKS

25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Batavia Biosciences
25.2.1. Company Snapshot
25.2.2. Interview Transcript: Menzo Havenga, Chief Executive Officer and President
25.3. CEVEC Pharmaceuticals
25.3.1. Company Snapshot
25.3.2. Interview Transcript: Nicole Faust, Chief Executive Officer & Chief Scientific Officer
25.4. Vigene Biosciences
25.4.1. Company Snapshot
25.4.2. Interview Transcript: Jeffrey Hung, Chief Commercial Officer
25.5. Delphi Genetics
25.5.1. Company Snapshot
25.5.2. Interview Transcript: Cedric Szpirer, Founder, Executive & Scientific Director
25.6. Clean Cells
25.6.1. Company Snapshot
25.6.2. Interview Transcript: Olivier Boisteau, Co-Founder / President, Laurent Ciavatti, Ex-Business Development Manager and Xavier Leclerc, Head of Gene Therapy
25.7. Novasep
25.7.1. Company Snapshot
25.7.2. Interview Transcript: Alain Lamproye, Ex-President of Biopharma Business Unit
25.8. Amsterdam BioTherapeutics Unit (AmBTU)
25.8.1. Organization Snapshot
25.8.2. Interview Transcript: Joost van den Berg, Ex-Director
25.9. MGH Viral Vector Development Facility, Massachusetts General Hospital
25.9.1. Organization Snapshot
25.9.2. Interview Transcript: Bakhos A Tannous, Director
25.10. Translational Vector Core, University of Nantes
25.10.1. Organization Snapshot
25.10.2. Interview Transcript: Eduard Ayuso, DVM, PhD, Scientific Director
25.11. CJ PARTNERS
25.11.1. Company Snapshot
25.11.2. Interview Transcript: Colin Lee Novick, Managing Director
25.12. ACGT
25.12.1. Company Snapshot
25.12.2. Interview Transcript: Semyon Rubinchik, Scientific Director
25.13. Richter-Helm
25.13.1. Company Snapshot
25.13.2. Interview Transcript: Astrid Brammer, Senior Manager Business Development
25.14. Plasmid Factory
25.14.1. Company Snapshot
25.14.2. Interview Transcript: Marco Schmeer, Project Manager and Tatjana Buchholz, Ex-Marketing Manager
25.15. Waisman Biomanufacturing
25.15.1. Company Snapshot
25.15.2. Interview Transcript: Brian M Dattilo, Business Development Manager
25.16. EFS-West Biotherapy
25.16.1. Company Snapshot
25.16.2. Interview Transcript: Beatrice Araud, ATMP Key Account Manager
25.17. GEG Tech
25.17.1. Company Snapshot
25.17.2. Interview Transcript: Nicolas Grandchamp, R&D Leader

26. APPENDIX I: TABULATED DATA

27. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures
Figure 3.1 Viral and Non-Viral Techniques for Gene Transfer
Figure 3.2 Vector Production: Types of Manufacturers
Figure 3.3 Viral Vectors: Manufacturing Process
Figure 4.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 4.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 4.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Figure 4.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Countries-wise)
Figure 4.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 4.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise )
Figure 4.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Countries-wise )
Figure 4.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production and Company Size
Figure 4.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Figure 4.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Manufactured
Figure 4.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 5.1 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 5.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 5.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Continents)
Figure 5.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Countries)
Figure 5.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 5.6 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Continents)
Figure 5.7 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Countries)
Figure 5.8 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production
Figure 5.9 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Figure 5.10 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 6.1 Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
Figure 6.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Continents)
Figure 6.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Countries)
Figure 6.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Purpose of Production and Location of Vector Manufacturing Facilities
Figure 6.5 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Production
Figure 6.6 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Figure 6.7 Logo Landscape: Distribution by Scale of Production and Type of Vector Manufactured
Figure 6.8 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Figure 7.1 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Figure 7.2 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Figure 7.3 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Production
Figure 7.4 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector Manufactured
Figure 7.5 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Figure 7.6 Most Active Players: Distribution by Type of Technology
Figure 8.1 Company Competitiveness Analysis: Distribution of Players based in North America (In-House Manufacturers)
Figure 8.2 Company Competitiveness Analysis: Distribution of Players based in Europe (In-House Manufacturers)
Figure 8.3 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (In-House Manufacturers)
Figure 8.4 Company Competitiveness Analysis: Distribution of Players based in North America (Contract Manufacturing Organizations)
Figure 8.5 Company Competitiveness Analysis: Distribution of Players based in Europe (Contract Manufacturing Organizations)
Figure 8.6 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (Contract Manufacturing Organizations)
Figure 8.7 Company Competitiveness Analysis: Distribution of Players based in North America (Both In-House and Contract Manufacturing Organizations)
Figure 8.8 Company Competitiveness Analysis: Distribution of Players based in Europe (Both In-House and Contract Manufacturing Organizations)
Figure 8.9 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (Both In-House and Contract Manufacturing Organizations)
Figure 9.1 Merck KGaA: Annual Revenues, 2014 - H1 2020 (EUR Billion)
Figure 9.2 Merck KGaA: Annual Revenues by Business Sector, 2019 (EUR Billion)
Figure 9.3 H.A.V.E.: AAV Vector Manufacturing Technology
Figure 9.4 bluebird bio: Annual Revenues, 2014 - H1 2020 (USD Million)
Figure 9.5 Emergent BioSolutions: Annual Revenues, 2016 - 9M 2020 (USD Million)
Figure 9.6 FUJIFILM Holdings: Annual Revenues, 2013 - Q1 FY 2021 (JPY Billion)
Figure 9.7 FUJIFILM Holdings: Revenues by Business Divisions, FY 2020 (JPY Billion)
Figure 9.8 Spark Therapeutics: Annual Revenues, 2014 - 9M 2019 (USD Million)
Figure 10.1 Lonza: Annual Revenues, 2014 - H1 2020 (CHF Billion)
Figure 10.2 MolMed: Annual Revenues, 2013 - H1 2020 (EUR Million)
Figure 10.3 Novasep: Annual Revenues, 2013 - 10 M 2018 (EUR Million)
Figure 10.4 Novasep: Viral Vector Manufacturing Process
Figure 10.5 Oxford BioMedica: Annual Revenues, 2014 - H1 2020 (GBP Million)
Figure 10.6 Sanofi: Annual Revenues, 2014 - H1 2020 (EUR Billion)
Figure 10.7 uniQure: Annual Revenues, 2014 - H1 2020 (USD Million)
Figure 11.1 Wuxi AppTec: Annual Revenues, 2017 - H1 2020 (RMB Million)
Figure 12.1 Recent Partnerships: Cumulative Year-wise Trend, 2015 - 2020 (till September)
Figure 12.2 Recent Partnerships: Distribution by Type of Partnership, 2015 - 2020 (till September)
Figure 12.3 Recent Partnerships: Distribution by Type and Year of Partnership, 2015 - 2020 (till September)
Figure 12.4 Recent Partnerships: Distribution by Scale of Operation
Figure 12.5 Recent Partnerships: Distribution by Type of Vector(s)
Figure 12.6 Recent Partnerships: Distribution by Therapeutic Area
Figure 12.7 Most Active Players: Distribution by Number of Partnerships
Figure 12.8 Recent Partnerships: Geographical Analysis
Figure 12.9 Recent Partnerships: Intercontinental and Intracontinental Agreements
Figure 13.1 Recent Expansions: Cumulative Year-wise Trend, 2015 - 2020 (till September)
Figure 13.2 Recent Expansions: Distribution by Type of Expansion, 2015 - 2020 (till September)
Figure 13.3 Recent Expansions: Distribution by Type and Year of Expansion, 2015 - 2020 (till September)
Figure 13.4 Recent Expansions: Distribution of Amount Invested by Key Players
Figure 13.5 Recent Expansions: Distribution by Scale of Operation
Figure 13.6 Recent Expansions: Distribution by Type of Vector(s)
Figure 13.7 Recent Expansions: Distribution by Application Area
Figure 13.8 Most Active Players: Distribution by Number of Expansions
Figure 13.9 Recent Expansions: Intercontinental and Intracontinental Expansions
Figure 13.10 Recent Expansions: Distribution by Location of Expansion Project
Figure 16.1 Vector and Gene Therapy Manufacturers: Competitive Landscape by Purpose of Production, Type of Vector Manufactured and Scale of Operation
Figure 16.2 Vector and Gene Therapy Manufacturers: Logo Landscape by Company Size and Type of Vector Manufactured
Figure 16.3 Vector and Gene Therapy Contract Manufacturers: Distribution by Prominent Geographical Hubs
Figure 16.4 Vector and Gene Therapy In-House Manufacturers: Distribution by Prominent Geographical Hubs
Figure 16.5 AAV Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 16.6 Adenoviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 16.7 Lentiviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 16.8 Retroviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 16.9 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.1 Viral Vector and Plasmid DNA Cost Price Analysis: Vector Production Process and Relative Costs Involved
Figure 18.1 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector Manufactured (in Liters)
Figure 18.2 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (in Liters)
Figure 18.3 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 18.4 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 18.5 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (in Liters)
Figure 18.6 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 18.7 Global Installed Viral Vector Manufacturing Capacity: Distribution by Scale of Production (in Liters)
Figure 18.8 Global Installed Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Viral Vector Manufacturing Facilities (in Liters)
Figure 18.9 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (in Liters)
Figure 18.10 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 18.11 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Scale of Production
Figure 18.12 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Plasmid DNA Manufacturing Facilities (in Liters)
Figure 19.1 Global Clinical Demand for Viral Vector and Plasmid DNA, 2021-2030 (Thousand Patients)
Figure 19.2 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Figure 19.3 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 19.4 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 19.5 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Figure 19.6 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients)
Figure 19.7 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Figure 19.8 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 19.9 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 19.10 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Figure 19.11 Global Viral Vector Manufacturing: Demand and Supply (Scenario 1), 2021-2030
Figure 19.12 Global Viral Vector Manufacturing: Demand and Supply (Scenario 2), 2021-2030
Figure 19.13 Global Viral Vector Manufacturing: Demand and Supply (Scenario 3), 2021-2030
Figure 20.1 Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030 (USD Million)
Figure 20.2 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Figure 20.3 Viral Vector and Plasmid DNA Manufacturing Market: Market Attractiveness Analysis by Type of Vector Manufactured, 2021-2030
Figure 20.4 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.5 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, 2021, 2025 and 2030 (USD Million)
Figure 20.6 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 20.7 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Purpose of Production, 2021-2030 (USD Million)
Figure 20.8 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.9 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.10 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021, 2025 and 2030 (USD Million)
Figure 20.11 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021, 2025 and 2030 (USD Million)
Figure 20.12 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Type of Vector Manufactured, 2021, 2025 and 2030 (USD Million)
Figure 20.13 AAV Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.14 AAV Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 20.15 AAV Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.16 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.17 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 20.18 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.19 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.20 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 20.21 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.22 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.23 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 20.24 Retroviral Vector Manufacturing Market for Commercial Product: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.25 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.26 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 20.27 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.28 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.29 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Figure 20.30 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021, 2025 and 2030 (USD Million)
Figure 20.31 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Figure 20.32 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.33 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Figure 20.34 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.35 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.36 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Figure 20.37 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.38 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.39 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Figure 20.40 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.41 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.42 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Figure 20.43 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.44 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.45 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Figure 20.46 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.47 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.48 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Therapeutic Area, 2021, 2025 and 2030 (USD Million)
Figure 20.49 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Animal Model Used, 2021-2030 (USD Million)
Figure 20.50 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021, 2025 and 2030 (USD Million)
Figure 20.51 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Figure 20.52 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.53 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Figure 20.54 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.55 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.56 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Figure 20.57 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.58 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.59 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Figure 20.60 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.61 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.62 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Figure 20.63 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.64 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Figure 20.65 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Figure 20.66 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 20.67 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Figure 20.68 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 20.69 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 20.70 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Figure 21.1 Viral Vectors and Plasmid DNA Manufacturing Market: COVID-19 Impact Informed Scenario, 2021-2030 (USD Billion)
Figure 22.1 Key Drivers and Challenges: AAV Vectors
Figure 22.2 Key Drivers and Challenges: Adenoviral Vectors
Figure 22.3 Key Drivers and Challenges: Lentiviral Vectors
Figure 22.4 Key Drivers and Challenges: Retroviral Vectors
Figure 22.5 Key Drivers and Challenges: Plasmid DNA
Figure 23.1 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 23.2 Survey Analysis: Distribution by Scale of Production
Figure 23.3 Survey Analysis: Distribution by Type of Vector Manufactured
Figure 24.1 Viral Vectors and Plasmid DNA Market: Distribution by Type of Vector Manufactured, 2021, 2025 and 2030 (USD Million)

List of Tables
Table 3.1 Key Features of Viral Vectors
Table 3.2 Key Features of Small-scale Cell Culture Systems
Table 4.1 Viral Vector and Gene Therapy Manufacturers: List of Industry Players
Table 4.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Location of Viral Vector Manufacturing Facilities, Scale of Production and Purpose of Production
Table 4.3 Heat Map: Information on Location of Headquarters and Scale of Production
Table 4.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Type of Viral Vector Manufactured
Table 4.5 Heat Map: Information on Scale of Production and Type of Viral Vector Manufactured
Table 4.6. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 4.7. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 5.1 Plasmid DNA and Gene Therapy Manufacturers: List of Industry Players
Table 5.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Company Size and Location of Headquarters
Table 5.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Location of Plasmid DNA Manufacturing Facilities, Scale of Production and Purpose of Production
Table 5.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 5.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 6.1 Vector and Gene Therapy Manufacturers: List of Non-Industry Players
Table 6.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Scale of Production
Table 6.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Type of Vector Manufactured
Table 6.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Application Area
Table 7.1 Vector and Gene Therapy Manufacturing Technologies: List of Technology Platforms
Table 9.1 Vector and Gene Therapy Production in North America: List of Profiled Companies
Table 9.2 Advanced BioScience Laboratories: Recent Developments and Future Outlook
Table 9.3 Aldevron Plasmid DNA: QC Assays
Table 9.4 Aldevron: Recent Developments and Future Outlook
Table 9.5 Audentes Therapeutics: Recent Developments and Future Outlook
Table 9.6 BioReliance / SAFC Commercial (Merck KGaA): Recent Developments and Future Outlook
Table 9.7 bluebird bio: Recent Developments and Future Outlook
Table 9.8 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 9.9 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 9.10 MeiraGTx: Recent Developments and Future Outlook
Table 9.11 MassBiologics: Recent Developments and Future Outlook
Table 9.12 Spark Therapeutics: Recent Developments and Future Outlook
Table 9.13 Vigene Biosciences: Recent Developments and Future Outlook
Table 10.1 Vector and Gene Therapy Production in Europe: List of Players Profiled
Table 10.2 Biovian: Recent Developments and Future Outlook
Table 10.3 Centre for Process Innovation: Recent Developments and Future Outlook
Table 10.4 Cobra Biologics: Recent Developments and Future Outlook
Table 10.5 FinVector: Recent Developments and Future Outlook
Table 10.6 Kaneka Eurogentec: Recent Developments and Future Outlook
Table 10.7 Lonza: Recent Developments and Future Outlook
Table 10.8 MolMed: Recent Developments and Future Outlook
Table 10.9 Novasep: Manufacturing Experience
Table 10.10 Novasep: Recent Developments Future Outlook
Table 10.11 Orchard Therapeutics: Recent Developments Future Outlook
Table 10.12 Oxford BioMedica: Recent Developments and Future Outlook
Table 10.13 Richter-Helm: Recent Developments and Future Outlook
Table 10.14 Sanofi: Recent Developments and Future Outlook
Table 10.15 uniQure: Recent Developments and Future Outlook
Table 10.16 Vibalogics: Recent Developments and Future Outlook
Table 10.17 VIVEbiotech: Recent Developments and Future Outlook
Table 10.18 Cell and Gene Therapy Catapult: Recent Developments and Future Outlook
Table 11.1 Wuxi AppTec: Recent Developments and Future Outlook
Table 11.2 List of Other Key Players Based in Asia Pacific
Table 12.1 Vector and Gene Therapy Manufacturing: List of Recent Partnerships, 2015-2020 (till September)
Table 12.2 Vector and Gene Therapy Manufacturing: List of Other Partnerships, 2015-2020 (till September)
Table 13.1 Vector and Gene Therapy Manufacturing: List of Recent Expansions, 2015-2020 (till September)
Table 13.2 Vector and Gene Therapy Manufacturing: Information on Scale of Production, Type of Vector Manufactured and Application Area, 2015-2020 (till September)
Table 14.1 AAV Vector-based Therapy Developers: Most Likely Partners
Table 14.2 AAV Vector-based Therapy Developers: Likely Partners
Table 14.3 AAV Vector-based Therapy Developers: Less Likely Partners
Table 14.4 AAV Vector-based Therapy Developers: Least Likely Partners
Table 14.5 Adenoviral Vector-based Therapy Developers: Most Likely Partners
Table 14.6 Adenoviral Vector-based Therapy Developers: Likely Partners
Table 14.7 Adenoviral Vector-based Therapy Developers: Less Likely Partners
Table 14.8 Adenoviral Vector-based Therapy Developers: Least Likely Partners
Table 14.9 Lentiviral Vector-based Therapy Developers: Most Likely Partners
Table 14.10 Lentiviral Vector-based Therapy Developers: Likely Partners
Table 14.11 Lentiviral Vector-based Therapy Developers: Less Likely Partners
Table 14.12 Lentiviral Vector-based Therapy Developers: Least Likely Partners
Table 14.13 Retroviral Vector-based Therapy Developers: Most Likely Partners
Table 14.14 Retroviral Vector-based Therapy Developers: Likely Partners
Table 14.15 Retroviral Vector-based Therapy Developers: Less Likely Partners
Table 14.16 Retroviral Vector-based Therapy Developers: Least Likely Partners
Table 14.17 Other Viral Vector-based Therapy Developers: Most Likely Partners
Table 14.18 Other Viral Vector-based Therapy Developers: Likely Partners
Table 14.19 Other Viral Vector-based Therapy Developers: Less Likely Partners
Table 14.20 Other Viral Vector-based Therapy Developers: Least Likely Partners
Table 14.21 AAV Vector Purification Product Developers: Most Likely Partners
Table 14.22 AAV Vector Purification Product Developers: Likely Partners
Table 14.23 Adenoviral Vector Purification Product Developers: Most Likely Partners
Table 14.24 Adenoviral Vector Purification Product Developers: Likely Partners
Table 14.25 Lentiviral Vector Purification Product Developers: Most Likely Partners
Table 14.26 Lentiviral Vector Purification Product Developers: Likely Partners
Table 14.27 Retroviral Vector Purification Product Developers: Most Likely Partners
Table 14.28 Retroviral Vector Purification Product Developers: Likely Partners
Table 14.29 Other Viral Vector Purification Product Developers: Most Likely Partners
Table 14.30 Other Viral Vector Purification Product Developers: Likely Partners
Table 17.1 Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions / Primary Research
Table 17.2 Viral Vector and Plasmid DNA: Prices of Vectors
Table 18.1 Global Installed Viral Vector Manufacturing Capacity: Sample Data Set
Table 18.2 Global Installed Plasmid DNA Manufacturing Capacity: Sample Data Set
Table 18.3 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size
Table 18.4 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 19.1. Global Viral Vectors Manufacturing Annual Demand, 2021-2030 (1020 vg)
Table 19.2 Global Viral Vectors Manufacturing Annual Supply (Scenario 1), 2021-2030 (1020 vg)
Table 19.3 Global Viral Vector Manufacturing: Annual Supply (Scenario 2), 2021-2030 (1020 vg)
Table 19.4 Global Viral Vector Manufacturing: Annual Supply (Scenario 3), 2021-2030 (1020 vg)
Table 20.1 Viral Vector and Plasmid DNA: Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 20.2 Viral Vector and Plasmid DNA: Distribution by Patients Enrolled in the Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 20.3 Viral Vector and Plasmid DNA: Number of Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2021-2030
Table 20.4 Viral Vector and Plasmid DNA: Number of Patients Enrolled in Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2021-2030
Table 20.5 Viral Vector and Plasmid DNA: Approved / Late-Stage Cell and Gene Therapies
Table 23.1 Survey Response: Overview of the Participating Companies / Organizations
Table 23.2 Survey Response: Seniority Level of Respondents
Table 23.3 Survey Response: Type of Vector
Table 23.4 Survey Response: Scale of Production
Table 23.5 Survey Response: Vector Stabilization Technology
Table 23.6 Survey Response: Purpose of Production (In-house Production versus Contract Services)
Table 25.1 Batavia Biosciences: Key Highlights
Table 25.2 CEVEC Pharmaceuticals: Key Highlights
Table 25.3 Vigene Biosciences: Key Highlights
Table 25.4 Delphi Genetics: Key Highlights
Table 25.5 Clean Cells: Key Highlights
Table 25.6 Novasep: Key Highlights
Table 25.7 Amsterdam BioTherapeutics Unit (AmBTU): Key Highlights
Table 25.8 MGH Viral Vector Development Facility, Massachusetts General Hospital: Key Highlights
Table 25.9 Translational Vector Core, University of Nantes: Key Highlights
Table 25.10 CJ PARTNERS: Key Highlights
Table 25.11 ACGT: Key Highlights
Table 25.12 Richter-Helm: Key Highlights
Table 25.13 Plasmid Factory: Key Highlights
Table 25.14 Waisman Biomanufacturing: Key Highlights
Table 25.15 EFS-West Biotherapy: Key Highlights
Table 25.16 GEG Tech: Key Highlights
Table 26.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 26.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 26.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continents-wise)
Table 26.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Countries-wise)
Table 26.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 26.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continents-wise)
Table 26.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Countries-wise)
Table 26.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production and Company Size
Table 26.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Table 26.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Manufactured
Table 26.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 26.12 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 26.13 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 26.14 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Continents)
Table 26.15 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Countries)
Table 26.16 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 26.17 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Continents)
Table 26.18 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Countries)
Table 26.19 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production
Table 26.20 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Table 26.21 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 26.22 Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
Table 26.23 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Continents)
Table 26.24 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Countries)
Table 26.25 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Purpose of Production and Location of Vector Manufacturing Facilities
Table 26.26 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Production
Table 26.27 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Table 26.28 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Production and Type of Vector Manufactured
Table 26.29 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Table 26.30 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Table 26.31 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Table 26.32 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Production
Table 26.33 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector Manufactured
Table 26.34 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Table 26.35 Most Active Players: Distribution by Type of Technology
Table 26.36 Merck KGaA: Annual Revenues, 2014 - H1 2020 (EUR Billion)
Table 26.37 Merck KGaA: Annual Revenues by Business Sector, 2019 (EUR Billion)
Table 26.38 bluebird bio: Annual Revenues, 2014 - H1 2020 (USD Million)
Table 26.39 Emergent BioSolutions: Annual Revenues, 2016 - 9M 2020 (USD Million)
Table 26.40 FUJIFILM Holdings: Annual Revenues, 2013 - Q1 FY 2021 (JPY Billion)
Table 26.41 FUJIFILM Holdings: Revenues by Business Divisions, FY 2020 (JPY Billion)
Table 26.42 Spark Therapeutics: Annual Revenues, 2014 - 9M 2019 (USD Million)
Table 26.43 Lonza: Annual Revenues, 2014 - H1 2020 (CHF Billion)
Table 26.44 MolMed: Annual Revenues, 2013 - H1 2020 (EUR Million)
Table 26.45 Novasep: Annual Revenues, 2013 - 10M 2018 (EUR Million)
Table 26.46 Oxford BioMedica: Annual Revenues, 2014-H1 2020 (GBP Million)
Table 26.47 Sanofi: Annual Revenues, 2014 - H1 2020 (EUR Billion)
Table 26.48 uniQure: Annual Revenues, 2014 - H1 2020 (USD Million)
Table 26.49 Wuxi AppTec: Annual Revenues, 2017 - H1 2020 (RMB Million)
Table 26.50 Recent Partnerships: Cumulative Year-wise Trend, 2015 - 2020 (till September)
Table 26.51 Recent Partnerships: Distribution by Type of Partnership, 2015 - 2020 (till September)
Table 26.52 Recent Partnerships: Distribution by Type and Year of Partnership, 2015 - 2020 (till September)
Table 26.53 Recent Partnerships: Distribution by Scale of Operation
Table 26.54 Recent Partnerships: Distribution by Type of Vector
Table 26.55 Recent Partnerships: Distribution by Therapeutic Area
Table 26.56 Most Active Players: Distribution by Number of Partnerships
Table 26.57 Recent Partnerships: Geographical Analysis
Table 26.58 Recent Partnerships: Intercontinental and Intracontinental Agreements
Table 26.59 Recent Expansions: Cumulative Year-wise Trend, 2015 - 2020 (till September)
Table 26.60 Recent Expansions: Distribution by Type of Expansion, 2015 - 2020 (till September)
Table 26.61 Recent Expansions: Distribution by Type and Year of Expansion, 2015 - 2020 (till September)
Table 26.62 Recent Expansions: Distribution of Amount Invested by Key Players
Table 26.63 Recent Expansions: Distribution by Scale of Operation
Table 26.64 Recent Expansions: Distribution by Type of Vector
Table 26.65 Recent Expansions: Distribution by Application Area
Table 26.66 Most Active Players: Distribution by Number of Expansions
Table 26.67 Recent Expansions: Intercontinental and Intracontinental Expansions
Table 26.68 Recent Expansions: Distribution by Location of Expansion Project
Table 26.69 Viral Vector and Plasmid DNA Cost Price Analysis: Vector Production Process and Relative Costs Involved
Table 26.70 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector Manufactured (in Liters)
Table 26.71 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (in Liters)
Table 26.72 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 26.73 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 26.74 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (in Liters)
Table 26.75 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 26.76 Global Installed Viral Vector Manufacturing Capacity: Distribution by Scale of Production (in Liters)
Table 26.77 Global Installed Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Viral Vector Manufacturing Facilities (in Liters)
Table 26.78 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (in Liters)
Table 26.79 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 26.80 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Scale of Production (in Liters)
Table 26.81 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Plasmid DNA Manufacturing Facilities (in Liters)
Table 26.82 Global Clinical Demand for Viral Vector and Plasmid DNA, 2021-2030 (Thousand Patients)
Table 26.83 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Table 26.84 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 26.85 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 26.86 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 26.87 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients)
Table 26.88 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector (Thousand Patients)
Table 26.89 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 26.90 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 26.91 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 26.92 Global Viral Vector Manufacturing: Demand and Supply (Scenario 1), 2021-2030
Table 26.93 Global Viral Vector Manufacturing: Demand and Supply (Scenario 2), 2021-2030
Table 26.94 Global Viral Vector Manufacturing: Demand and Supply (Scenario 3), 2021-2030
Table 26.95 Viral Vector and Plasmid DNA Manufacturing Market, 2021-2030 (USD Million)
Table 26.96 Viral Vector and Plasmid DNA Manufacturing: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Table 26.97 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.98 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, 2021, 2025 and 2030 (USD Million)
Table 26.99 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 26.100 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Purpose of Production, 2021-2030 (USD Million)
Table 26.101 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.102 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.103 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Product: Distribution by Therapeutic Area, 2021, 2025 and 2030 (USD Million)
Table 26.104 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021, 2025 and 2030 (USD Million)
Table 26.105 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Type of Vector Manufactured, 2021, 2025 and 2030 (USD Million)
Table 26.106 AAV Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.107 AAV Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 26.108 AAV Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.109 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.110 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 26.111 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.112 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.113 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 26.114 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.115 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.116 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 26.117 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.118 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.119 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 26.120 Plasmid DNA Vector Manufacturing Market for Commercial Products, 2021-2030: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.121 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.122 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Phase of Development, 2021-2030 (USD Million)
Table 26.123 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2020, 2025 and 2030 (USD Million)
Table 26.124 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, 2021-2030: Distribution by Type of Vector, 2021-2030 (USD Million)
Table 26.125 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.126 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Table 26.127 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.128 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.129 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Table 26.130 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.131 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.132 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Table 26.133 Lentiviral Vector Manufacturing Market for Clinical Candidate: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.134 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.135 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Table 26.136 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.137 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.138 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2021-2030 (USD Million)
Table 26.139 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.140 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2021-2030: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.141 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Therapeutic Area, 2021, 2025 and 2030 (USD Million)
Table 26.142 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Animal Model Used, 2021-2030 (USD Million)
Table 26.143 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Geography, 2021, 2025 and 2030 (USD Million)
Table 26.144 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Table 26.145 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.146 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Table 26.147 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.148 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.149 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Table 26.150 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.151 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.152 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Table 26.153 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.154 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.155 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Table 26.156 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.157 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2021-2030 (USD Million)
Table 26.158 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2021-2030 (USD Million)
Table 26.159 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.160 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Type of Vector Manufactured, 2021-2030 (USD Million)
Table 26.161 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 20.162 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 26.163 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Key Geographical Regions, 2021-2030 (USD Million)
Table 26.164 Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2030: COVID-19 Impact Informed Scenario (USD Billion)
Table 26.165 Survey Analysis: Distribution by Seniority Level of Respondents
Table 26.166 Survey Analysis: Distribution by Scale of Production
Table 26.167 Survey Analysis: Distribution by Type of Vector Manufactured
Table 26.168 Viral Vectors and Plasmid DNA Market: Distribution by Type of Vector Manufactured, 2021, 2025, 2030 (USD Million)

Note: Product cover images may vary from those shown
  • 4D Molecular Therapeutics
  • Abbott
  • AbbVie
  • Abeona Therapeutics
  • Abintus Bio
  • Accinov(acquired by ABL Europe)
  • Acucela
  • Adaptimmune Therapeutics
  • AdaptVac
  • Addgene
  • Aduro Biotech
  • Advanced BioScience Laboratories
  • Advanced Biotherapeutics Consulting
  • Advantagene
  • Advaxis
  • Advent
  • Adverum Biotechnologies
  • Aevitas Therapeutics (a subsidiary of Fortress Biotech)
  • AffyImmune Therapeutics
  • AGC Biologics
  • Agenzia Italiana del Farmaco
  • Agilent Technologies
  • Agilis Biotherapeutics (acquired by PTC Therapeutics)
  • Ajinomoto Althea
  • Akdeniz University
  • Akron Biotech
  • Aldevron
  • Allele Biotechnology
  • Allergan
  • Allife Medicine
  • Allogene Therapeutics
  • Alma Bio Therapeutics
  • AlphaVax
  • ALSTEM
  • Althea Technologies
  • Altimmune
  • Altor BioScience
  • American Gene Technologies
  • Amgen
  • Amicus Therapeutics
  • Ampersand Capital Partners
  • AMSBIO
  • Amsterdam BioTherapeutics Unit
  • Amsterdam Molecular Therapeutics ( acquired by uniQure)
  • Anaeropharma Science
  • Anemocyte
  • AnGes
  • Angionetics
  • Annapurna Therapeutics ( acquired by Avalanche Biotechnologies)
  • apceth Biopharma
  • ApollobBo
  • Applied Biological Materials
  • Applied Genetic Technologies (AGTC)
  • Applied Viromics
  • Arcellx
  • ARCO Design/Build
  • ArcticZymes Technologies
  • Areta International
  • Aruvant Sciences
  • ASC Therapeutics
  • Asklepios BioPharmaceutical
  • Astellas Pharma
  • AstraZeneca
  • Atara Biotherapeutics
  • Atlantic Bio
  • Atsena Therapeutics
  • ATVIO Biotech
  • Audentes Therapeutics
  • Aurora Biopharma
  • Autolus Therapeutics
  • Avecia Biologics
  • AveXis
  • AVROBIO
  • Axovant Gene Therapies
  • Bamboo Therapeutics
  • Batavia Biosciences
  • Baylor College of Medicine
  • BCM Families Foundation
  • Beam Therapeutics
  • Beckman Research Institute
  • Beijing Biohealthcare Biotechnology
  • Beijing Doing Biomedical
  • Beijing HuiNengAn Biotech
  • Beijing Immunochina Medical Science & Technology
  • Beijing Mario Biotechnology
  • Beijing Sanwater Biological Technology
  • Bellicum Pharmaceuticals
  • Benitec Biopharma
  • BIA Separations
  • Bio-Gene Technology
  • Bio-Rad Laboratories
  • Bioceltech Therapeutics
  • BioCentriq
  • Biogen
  • BioInvent International
  • BioMarin Pharmaceutical
  • Biomay
  • Biomiga
  • Bionic Sight
  • BioNTech Innovative Manufacturing Service
  • BioReliance
  • BioVec Pharma
  • Bioverativ
  • Biovian
  • BioVision
  • Blue Sky BioServices
  • bluebird bio
  • Boehringer Ingelheim BioXcellence
  • BoYuan RunSheng Pharma
  • Brain Neurotherapy Bio
  • Brammer Bio
  • Bristol Myers Squibb
  • California Institute of Technology
  • Cambridge Gene Therapy
  • Cancer Research UK
  • Candel Therapeutics
  • Carina Biotech
  • Carmine Therapeutics
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • Casey Eye Institute
  • Castle Creek Biosciences
  • Catalent Biologics
  • Celgene
  • Cell and Gene Therapy Catapult
  • Cell Biolabs
  • Cellectis
  • CellGenTech
  • Cellular Biomedicine Group
  • CellVec
  • Celonic
  • Celsion
  • Celyad Oncology
  • Center for Breakthrough Medicines
  • Centre for Commercialization of Regenerative Medicine
  • Centre for Process Innovation
  • CEVEC Pharmaceuticals
  • CG Oncology
  • Children's Hospital of Philadelphia
  • Children’s Medical Research Institute (CMRI)
  • China Immunotech (Beijing) Biotechnology
  • Chongqing Precision Biotech
  • Choroideremia Research Foundation
  • Cincinnati Children's Hospital Medical Center
  • City of Hope
  • Clean Cells
  • Clinical BioManufacturing Facility (University of Oxford)
  • Clino
  • Cobra Biologics
  • Cognate BioServices
  • CombiGene
  • Copernicus Therapeutics
  • Cornell University
  • Creative Biogene
  • Creative Biolabs
  • CSL Behring
  • Cytiva
  • CytoMed Therapeutics
  • Daiichi Sankyo
  • Delphi Genetics
  • Denali Therapeutics
  • DINAQOR
  • DNAtrix
  • Duke University
  • Dyno Therapeutics
  • Editas Medicine
  • ElevateBio
  • Elixirgen Scientific
  • Emergent BioSolutions
  • Emory University School of Medicine
  • enGene
  • Epeius Biotechnologies
  • Errant Gene Therapeutics
  • Esteve
  • eTheRNA immunotherapies
  • EUFETS
  • Eureka Biotechnology
  • Eurofins Genomics
  • Eurofins Scientific
  • ExcellGene
  • Exothera
  • Expression Therapeutics
  • Eyevensys
  • Fate Therapeutics
  • FerGene
  • FIMA
  • FinVector
  • Five Prime Therapeutics
  • Flash Therapeutics
  • Flexion Therapeutics
  • Florida Biologix
  • Formula Pharmaceuticals
  • Fortress Biotech
  • Fosun Pharma
  • Foundation Fighting Blindness
  • Fraunhofer Institute for Toxicology and Experimental Medicine
  • Freeline Therapeutics
  • FUJIFILM Diosynth Biotechnologies
  • Fundamenta Therapeutics
  • GE Healthcare Life Sciences
  • GEG Tech
  • Gen-X
  • Genable Technologies
  • Gene Therapy Research Institution
  • GeneCopoeia
  • GeneCure Biotechnologies
  • GeneDetect
  • GeneImmune Biotechnology
  • Genelux
  • GeneMedicine
  • GeneOne Life Science
  • Genethon
  • GENEWIZ
  • Genexine
  • Genezen Laboratories
  • GenIbet Biopharmaceuticals
  • Genprex
  • GenScript
  • GenSight Biologics
  • GenVec
  • Genzyme
  • GeoVax Labs
  • GIGA
  • GlaxoSmithKline
  • Gracell Biotechnologies
  • Gradalis
  • Green Cross LabCell
  • Grousbeck Gene Therapy Center
  • Guangdong Xiangxue Precision Medical Technology
  • Guangdong Zhaotai InVivo Biomedicine
  • Guangzhou Anjie Biomedical Technology
  • Guangzhou FineImmune Biotechnology
  • Gyroscope Therapeutics
  • Hadassah Medical Organization
  • Handl Therapeutics
  • Harvard Gene Therapy Initiative
  • Hebei Senlang Biotechnology
  • Heidelberg University Hospital
  • Helixmith
  • Hemera Biosciences
  • Henan Hualong Biotechnology
  • Herantis Pharma
  • Hitachi Chemical Advanced Therapeutics Solutions
  • Holostem Terapie Avanzate
  • Homology Medicines
  • Hong Kong Institute of Biotechnology
  • Hookipa Biotech
  • HORAMA
  • Hrain Biotechnology
  • Huadao biomedical
  • Huapont Life Sciences
  • Human Stem Cells Institute (HSCI)
  • Hunan Zhaotai Yongren Medical Innovation
  • Icahn School of Medicine at Mount Sinai
  • iCAR Bio Therapeutics
  • iCarTAB BioMed
  • iCell Gene Therapeutics
  • ID Pharma
  • Ilya Pharma
  • Immatics
  • Immune Design
  • Immune Technology
  • Immunocore
  • Immunomic Therapeutics
  • Imperial Innovations
  • Indiana University
  • Innovative Cellular Therapeutics
  • Inovio Pharmaceuticals
  • InProTher
  • Institute of Medical Science Research Hospital
  • Institute of Translational Health Sciences
  • Instituto de Tecnologia Química e Biológica (ITQB)
  • International AIDS Vaccine Initiative (IAVI)
  • InvivoGen
  • IPPOX Foundation
  • IVERIC bio
  • Janssen Pharmaceuticals
  • Juno Therapeutics
  • Juventas Cell Therapy
  • JW Therapeutics
  • KAEDI
  • Kaneka Eurogentec
  • Karolinska Institutet
  • Kecellitics Biotech
  • King’s College London
  • Kite Pharma
  • Kobe Biomedical Innovation Cluster
  • Kolon TissueGene
  • Kriya Therapeutics
  • Krystal Biotech
  • Kuur Therapeutics
  • Laboratory of Digital Sciences of Nantes
  • LakePharma
  • Legend Biotech
  • Lentigen Technology
  • Leucid Bio
  • Leuven Viral Vector Core
  • LEXEO Therapeutics
  • Lion TCR
  • Lipigon Pharmaceuticals
  • LNBio
  • LogicBio Therapeutics
  • Lokon Pharma
  • Lonza
  • Louisiana State University School of Veterinary Medicine
  • Luina Bio
  • Luminous BioSciences
  • Lund University
  • Lysogene
  • Magee-Womens Research Institute
  • Maine Medical Center Research Institute (MMCRI)
  • Marino Biotechnology
  • Massachusetts Eye and Ear
  • Massachusetts General Hospital
  • MassBiologics
  • MaxCyte
  • Mayflower Bioscience
  • Mayo Clinic Cancer Center
  • MD Anderson Cancer Institute
  • Medac
  • Medigene
  • MedImmune
  • MeiraGTx
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Microsoft
  • Mila’s Miracle Foundation
  • MilliporeSigma
  • Milo Biotechnology
  • Miltenyi Biotec
  • Minerva Biotechnologies
  • MingJu Therapeutics
  • Mitsubishi Tanabe Pharma
  • Molecular Diagnostic Services
  • MolMed
  • Momotaro-Gene
  • MultiVir
  • Mustang Bio
  • Myeloma Crowd
  • Nanjing Bioheng Biotech
  • Nantes Gene Therapy Institute
  • Naobios
  • National Cancer Institute
  • National Center for Advancing Translational Sciences
  • National Eye Institute
  • National Human Genome Research Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Environmental Health Sciences
  • Nationwide Children's Hospital
  • Nature Technology
  • Naval Medical Research Center
  • Neurimmune
  • NeuroCure
  • Neurophth Therapeutics
  • Neuroscience Center Zurich
  • New Jersey Innovation Institute (NJII)
  • NewLink Genetics
  • NHS Blood and Transplant
  • Nikon CeLL innovation
  • Noga Therapeutics
  • Norgen Biotek
  • Nouscom
  • Novartis
  • Novasep
  • Odylia Therapeutics
  • Okairos
  • Omnia Biologics
  • Oncolys BioPharma
  • OncoSec
  • OncoSenX
  • ORCA Therapeutics
  • Orchard Therapeutics
  • Oregon Health & Science University
  • OS Therapies (OST)
  • Otonomy
  • Oxford BioMedica
  • Oxford Genetics
  • OXGENE
  • OZ Biosciences
  • PACT Pharma
  • Pall Biotech
  • Paragon Bioservices
  • PeriphaGen
  • PersonGen BioTherapeutics
  • Pfizer
  • PharmaCell
  • PhorMed
  • Pinze Lifetechnology
  • PlasmidFactory
  • Poseida Therapeutics
  • Precigen
  • Precision BioSciences
  • Prevail Therapeutics
  • ProBioGen
  • Progenics Pharmaceuticals
  • ProMab Biotechnologies
  • Protheragen
  • Provecs Medical
  • PsiOxus Therapeutics
  • PTC Therapeutics
  • Puresyn
  • Quethera
  • Regeneron Pharmaceuticals
  • REGENXBIO
  • ReiThera
  • Renova Therapeutics
  • Rentschler Biotechnologie
  • Richter-Helm BioLogics
  • Roche
  • Rocket Pharmaceuticals
  • Roswell Park Comprehensive Cancer Center
  • Rubius Therapeutics
  • SAB Technology
  • SAFC
  • Saiba
  • Salk Institute for Biological Studies
  • San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget)
  • Sanford Burnham Prebys Medical Discovery Institute
  • Sangamo Therapeutics
  • Sanofi
  • Santen Pharmaceutical
  • Sarepta Therapeutics
  • Sartorius Stedim Biotech
  • Scancell
  • Seattle Children's Research Institute
  • Selecta Biosciences
  • Servier
  • Shanghai Biomed-union Biotechnology
  • Shanghai Bioray Laboratory
  • Shanghai Cell Therapy
  • Shanghai GeneChem
  • Shanghai Longyao Biotechnology
  • Shanghai PerHum Therapeutics
  • Shanghai Sunway Biotech
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Shenzhen Binde Biotechnology
  • Shenzhen SiBiono GeneTech
  • SignaGen Laboratories
  • SillaJen
  • Simcere Pharmaceutical
  • Sinobioway Cell Therapy
  • SIRION Biotech
  • Solid Biosciences
  • Sorrento Therapeutics
  • Spark Therapeutics
  • SQZ Biotechnologies
  • St. Jude Children's Research Hospital
  • Stanford University
  • Symbiosis Pharmaceutical Services
  • Synpromics
  • Synthace
  • System Biosciences
  • Takara Bio
  • Takeda Pharmaceutical
  • Targovax
  • TCR2 Therapeutics
  • TCRCure Biopharma
  • tebu-bio
  • Telethon Institute of Genetics and Medicine (TIGEM)
  • Terry Fox Laboratory
  • Tessa Therapeutics
  • The Beijing Pregene Science and Technology
  • The Jackson Laboratory
  • The Jenner Institute
  • The Michael J. Fox Foundation
  • The Native Antigen
  • The Pregene (ShenZhen) Biotechnology
  • The University of Tennessee Health Science Center
  • TheraBiologics
  • Theravectys
  • Thermo Fisher Scientific
  • Tianjin Mycure Medical Technology
  • Timmune Biotech
  • Tmunity Therapeutics
  • Tolerion
  • Touchlight Genetics
  • Transgene
  • Treeway
  • Trizell
  • Twist Bioscience
  • TxCell
  • UC Davis
  • UC San Diego School of Medicine
  • UK Cystic Fibrosis Gene Therapy Consortium
  • Ultragenyx Pharmaceutical
  • uniQure
  • Universitat Autònoma de Barcelona-Vall d'Hebrón Institut de Recerca
  • University College London
  • University Medical Center Groningen
  • University of Adelaide
  • University of Eastern Finland
  • University of Florida
  • University of Iowa Carver College of Medicine
  • University of Massachusetts Medical School
  • University of Michigan Medical Center
  • University of Minnesota
  • University of North Carolina
  • University of Pennsylvania
  • University of Pittsburgh
  • University of South Carolina School of Medicine
  • University of Southampton
  • University of Tokyo
  • University of Virginia School of Medicine
  • Unum Therapeutics (now Cogent Biosciences)
  • Urovant Sciences
  • USC School of Pharmacy
  • UWELL Biopharma
  • Vaccine Manufacturing and Innovation Centre (VMIC)
  • Vaccitech
  • VBL Therapeutic
  • VCN Biosciences
  • Vector Biolabs
  • Vecura
  • VGXI
  • Vibalogics
  • Vical
  • Vigene Biosciences
  • Vineti
  • Viralgen
  • Virapur
  • ViraQuest
  • ViroMed
  • Virovek
  • VirusTech
  • VIVEbiotech
  • Voyager Therapeutics
  • Waisman Biomanufacturing
  • Washington University School of Medicine
  • Wellington Zhaotai Therapies
  • Wuhan Bio-Raid Biotechnology
  • Wuhan Sian Medical Technology
  • WuXi AppTec
  • Wyvern Pharmaceuticals
  • Xiangxue Life Sciences
  • Xpress Biologics
  • XyloCor Therapeutics
  • Xyphos Biosciences
  • Yake Biotechnology
  • Yposkesi
  • Yufan Biotechnology
  • Ziopharm Oncology
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll